Mineralys Therapeutics' aldosterone synthase inhibitor lorundrostat has an FDA action date scheduled for December 22, 2026.

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Drug pricing policy, insurance prior authorization, and essential drug shortages affecting medication affordability and access.